Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : STG-001
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Organovo Holdings
Deal Size : $57.0 million
Deal Type : Series A Financing
Details : This Series A financing enables Stargazer to advance development of STG-001 through a pivotal clinical efficacy study potentially leading to a new therapy for Stargardt Disease, a major cause of vision loss in children and young adults.
Product Name : STG-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : STG-001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Organovo Holdings
Deal Size : $57.0 million
Deal Type : Series A Financing
Reset All
